Aberrant (pro)renin receptor expression induces genomic instability in pancreatic ductal adenocarcinoma through upregulation of SMARCA5/SNF2H

Shibayama, Yuki; Takahashi, Kazuo; Yamaguchi, Hisateru; Yasuda, Jun; Yamazaki, Daisuke; Rahman, Asadur; Fujimori, Takayuki; Fujisawa, Yoshihide; Takai, Shinji; Furukawa, Toru; Nakagawa, Tsutomu; Ohsaki, Hiroyuki; Kobara, Hideki; Wong, Jing Hao; Masaki, Tsutomu; Yuzawa, Yukio; Kiyomoto, Hideyasu; Yachida, Shinichi; Fujimoto, Akihiro; Nishiyama, Akira

doi:10.1038/s42003-020-01434-x

Download PDF

Article
Open access
Published: 27 November 2020

Aberrant (pro)renin receptor expression induces genomic instability in pancreatic ductal adenocarcinoma through upregulation of SMARCA5/SNF2H

Yuki Shibayama¹,
Kazuo Takahashi²,
Hisateru Yamaguchi ORCID: orcid.org/0000-0002-4507-9598^3,4,
Jun Yasuda^5,6,
Daisuke Yamazaki¹,
Asadur Rahman ORCID: orcid.org/0000-0002-9172-5343¹,
Takayuki Fujimori^7,8,
Yoshihide Fujisawa⁹,
Shinji Takai¹⁰,
Toru Furukawa ORCID: orcid.org/0000-0002-1083-2324¹¹,
Tsutomu Nakagawa¹²,
Hiroyuki Ohsaki¹³,
Hideki Kobara⁷,
Jing Hao Wong¹⁴,
Tsutomu Masaki⁷,
Yukio Yuzawa²,
Hideyasu Kiyomoto¹⁵,
Shinichi Yachida¹⁶,
Akihiro Fujimoto¹⁴ &
…
Akira Nishiyama ORCID: orcid.org/0000-0001-5971-820X¹

Communications Biology volume 3, Article number: 724 (2020) Cite this article

21k Accesses
5 Citations
10 Altmetric
Metrics details

Subjects

Abstract

(Pro)renin receptor [(P)RR] has a role in various diseases, such as cardiovascular and renal disorders and cancer. Aberrant (P)RR expression is prevalent in pancreatic ductal adenocarcinoma (PDAC) which is the most common pancreatic cancer. Here we show whether aberrant expression of (P)RR directly leads to genomic instability in human pancreatic ductal epithelial (HPDE) cells. (P)RR-expressing HPDE cells show obvious cellular atypia. Whole genome sequencing reveals that aberrant (P)RR expression induces large numbers of point mutations and structural variations at the genome level. A (P)RR-expressing cell population exhibits tumour-forming ability, showing both atypical nuclei characterised by distinctive nuclear bodies and chromosomal abnormalities. (P)RR overexpression upregulates SWItch/Sucrose Non-Fermentable (SWI/SNF)-related, matrix-associated, actin-dependent regulator of chromatin, subfamily a, member 5 (SMARCA5) through a direct molecular interaction, which results in the failure of several genomic stability pathways. These data reveal that aberrant (P)RR expression contributes to the early carcinogenesis of PDAC.

Defining cellular complexity in human autosomal dominant polycystic kidney disease by multimodal single cell analysis

Article Open access 30 October 2022

Targetable NOTCH1 rearrangements in reninoma

Article Open access 25 September 2023

Super-enhancer-driven metabolic reprogramming promotes cystogenesis in autosomal dominant polycystic kidney disease

Article 13 July 2020

Introduction

Pancreatic ductal adenocarcinoma (PDAC) has a high rate of malignancy, with median survival of 6 months and 5-year survival remaining <10%¹. Somatically acquired mutations become a driving force to promote the progression of PDAC. On average, a PDAC patient acquires 67 nonsynonymous mutations². In particular, activating mutations of KRAS are almost ubiquitous and inactivating mutations of TP53, SMAD4, CDKN2A, genes related to chromatin modification are also prevalent among PDAC patients^2,3,4. Recent whole-genome analyses have detected large numbers of structural variations in PDAC^4,5. However, molecular mechanisms responsible for genome instability remains unclear.

Recently, we and others have shown that (pro)renin receptor [(P)RR] expression is aberrant in human PDAC tissues, irrespective of the PDAC stage^6,7. Furthermore, higher (P)RR expression was associated with severe stage in the TNM Classification of Malignant Tumours (TNM)⁶. Interestingly, aberrant (P)RR expression was synchronized with the appearance of atypical nuclei observed in pancreatic intraepithelial neoplasia (PanIN)-2 and PanIN-3 lesions^6,7, suggesting a potential role of (P)RR in genomic homeostasis.

(P)RR plays a role of multiple cellular functions, such as renin-angiotensin system, Wnt signalling pathway, extracellular and vesicular acidification, cell polarity and maintenance of the pyruvate dehydrogenase (PDH) complex⁸. The specific binding of prorenin and renin to the extracellular domain of (P)RR cleaves angiotensin I from angiotensinogen thus activating renin-angiotensin system⁹. It has also been shown that intracellular signals such as mitogen-activated protein (MAP) kinase are activated by ligands, independent of renin-angiotensin system^9,10,11. Moreover, the extracellular domain of (P)RR also has a molecular interaction with low-density lipoprotein receptor protein 6 (LRP6) and Frizzled 8 of Wnt receptor complex¹². The activation of Wnt signalling pathway through this molecular interaction is related to the development of PDAC^7,13, Glioma¹⁴. and colorectal cancer¹⁵. (P)RR plays a role in an accessary protein of vacuolar H⁺-ATPase (V-ATPase)¹⁶, which mediates the acidification of the extracellular space or vesicles to facilitate membrane trafficking and fusion, receptor-mediated endocytosis and autophagic protein degradation¹⁷. (P)RR is also involved in partitioning defective homologue 3 (Par3) system responsible for apical-basal orientation¹⁸ and noncanonical Wnt planar cell polarity (PCP) pathway for proximal-distal orientation^19,20 in the cellular polarity. Binding of the (P)RR to PDH E1β-subunit (PDHB) contributes to the maintenance of aerobic glucose metabolism²¹. However, whether these cellular functions dominantly affect the genomic instability under aberrant (P)RR expression remains to be solved.

In the present study, we explore whether aberrant (P)RR expression directly induces genomic instability responsible for the generation of tumour heterogeneity in human pancreatic ductal epithelial (HPDE) cells, which are capable of transforming into PDAC²². To determine the level of genomic instability associated with aberrant (P)RR expression, we performed whole-genome sequencing analysis for (P)RR-expressing HPDE cells. Using nanoscale liquid chromatography with tandem mass spectrometry (LC-MS/MS), we also elucidated the molecular mechanism of genomic instability induced by aberrant (P)RR expression. Through these analyses, we demonstrate that aberrant (P)RR expression directly induces genomic instability by the disorder of SWItch/Sucrose Non-Fermentable (SWI/SNF)-related, matrix-associated, actin-dependent regulator of chromatin, subfamily a, member 5 (SMARCA5) as a chromatin remodeller at the whole-genome level. The data reveal that inappropriate augmentation of (P)RR expression contributes to the genetic evolution of PDAC.

Results

Aberrant (P)RR expression generates diverse cellular atypia

We established (P)RR-overexpressing HPDE-1/E6E7²³ and -HPDE-6/E6E7²⁴ cells using a stable vector inserted with the coding sequence of ATP6ap2 encoding (P)RR to perform the following experiments. As a control, we included cells transfected by a vector without the insertion of ATP6ap2, referred to as Mock (Fig. 1a). The insertion of ATP6ap2 was confirmed in both cells at six-passage by PCR (Fig. 1a). Compared to cells with Mock, (P)RR overexpression significantly induced much larger and variable cell area (N = 100 for each; Student’s t-test; P < 0.0001 vs. Mock) in HPDE-1/E6E7 and HPDE-6/E6E7 cell population (Fig. 1b). (P)RR overexpression also exhibited nuclei with distinctive nuclear bodies (Fig. 1b). To evaluate the level of atypical nuclei in HPDE-1/E6E7 and HPDE-6/E6E7 cells, we performed Papanicolaou stain. In both cell populations under aberrant (P)RR expression, multi-nucleated cells were considerable and the increase of (P)RR expression significantly led to larger and variable nuclear area (N = 100 for each; Student’s t-test; P < 0.0001 vs. Mock; Fig. 1c and Supplementary Fig. 1). Chromosome abnormality was also observed in both cell populations expressing (P)RR (Fig. 1c and Supplementary Fig. 1). It is clear from the data that (P)RR-expressing HPDE-1/E6E7 and HPDE-6/E6E7 cell population generates cells harboring diverse atypical nuclei.

**Fig. 1: (P)RR-expressing HPDE-1/E6E7 and HPDE-6/E6E7 cell population exhibited cellular atypia.**

Genomic instability in HPDE cells with (P)RR overexpression

To compare genomic instability between HPDE-1/E6E7 cell population with transient and stable (P)RR expression, we also established (P)RR-overexpressing HPDE-1/E6E7 cells using a stable and non- replicative transient vector inserted with the coding sequence of ATP6ap2²⁵ (Fig. 2a). The insertion of ATP6ap2 was confirmed in HPDE-1/E6E7 cells with transient (P)RR expression by PCR (Fig. 2a).

**Fig. 2: Genomic instability of HPDE-1/E6E7 cell population with transient and stable (P)RR expression.**

We performed whole-genome sequencing for untreated, transient Mock- and (P)RR-overexpressing and stable Mock- and (P)RR-overexpressing HPDE-1/E6E7 cells. By comparing each Mock- and (P)RR-overexpressing cells against untreated HPDE-1/E6E7 cells, we detected point mutations, short insertions and deletions (indels), and structural variations (SVs). Our analyses identified much larger numbers of point mutations and SVs in stable (P)RR-overexpressing cells than other treated cells. Furthermore, stable (P)RR expression against transient (P)RR considerably induced higher numbers of somatic mutations and SVs than stable Mock expression against transient Mock. These data indicate that the level of (P)RR expression affects the difference in genomic instability (Fig. 2b, c and Supplementary Fig. 2 and Supplementary Data 1). Stable (P)RR-overexpressing cells increased the number of point mutations and SVs than stable Mock cells by 6.5- and 8.8- fold, respectively. Chromosomal translocations detected in the stable (P)RR-overexpressing cells numbered 122 and dominated in all the SVs (48%). However, there was no difference in the number of short indels among treated cells.

We next focused on protein alternating mutations in the stable (P)RR-overexpressing cells. Our analyses identified 63 nonsynonymous mutations, and known driver genes defined by the COSMIC database (https://cancer.sanger.ac.uk/cosmic; FGFR3, MLL3, BRIP1 and MSH6) were included (Supplementary Data 2). In the SVs, breakpoints were detected in 5 COSMIC driver genes (PDE4DIP, THRAP3, FANCD2, MDS1 and CBL; Supplementary Data 3). In addition, a chromosomal translocation was detected in a region close to a LINE1 transposable element located on intron1 of TTC28. Recurrent chromosomal translocation events in this region were reported in various cancers and were considered to be caused by LINE1 transposition^26,27,28. Another chromosomal translocation was observed in MACROD2 gene, which is located at a fragile site and can be related with DNA repair system through PARP1 poly ADP-ribosylation (PARylation)^29,30. These results suggest that (P)RR overexpression induces mutations in some important driver genes, which may contribute to genetic abbreviation in cancer.

(P)RR cell population exhibits tumour-forming ability

We examined whether implanted (P)RR-expressing HPDE-1/E6E7 cells possess pre-cancerous ability in vivo. For this purpose, 14-passage cells expressing either Mock or (P)RR were implanted into renal subcapsules of immunodeficient mice. The results from Sanger DNA sequencing and PCR products showed that mutations in KRAS codon 12^2,3,4 and in CDKN2A were absent in both Mock- and (P)RR-expressing cells (Fig. 3a). However, the (P)RR-expressing HPDE-1/E6E7 cell population began to form a tumour at 5 weeks after implantation, although explosive cell population growth was absent, owing to the absence of mutations in KRAS codons. On the other hand, visible expansion was entirely absent upon the implantation of Mock cells (Fig. 3b, c). Histological analysis revealed that tissues formed by (P)RR-expressing cell implantation were composed of atypical cells with different shapes (Fig. 3d, e and Supplementary Fig. 3). Furthermore, these cells were also characterised by atypical and swollen nuclei with distinctive nuclear bodies and chromosomal abnormalities, such as bridge and fusion of the breakage-fusion-bridge (BFB) cycle induced by telomere dysfunction³¹ (Fig. 3d, e). These results demonstrate that the (P)RR-expressing HPDE-1/E6E7 cell population exhibits tumour-forming ability in vivo.

**Fig. 3: Tumour-forming ability in (P)RR-expressing HPDE-1/E6E7 cell population.**

Intracellular localization of (P)RR

To elucidate the intracellular localization of each domain of (P)RR after cleavage by a protease such as furin^7,32, we conducted immunofluorescence in the human PDAC cell lines PK-1, PANC-1 and MiaPaCa-2 and (P)RR-expressing HPDE-1/E6E7 cells using two anti-ATP6AP2 antibodies that recognize different domains of (P)RR. Anti-ATP6AP2 antibody interacts with an immunogen corresponding to a region within amino acids (a.a.) 146 and 350, covering from the extracellular to cytoplasmic domains of (P)RR, which detects all the full-length (P)RR [FL (P)RR], N-terminal fragment (NTF) and C-terminal fragment (CTF). The other antibody recognizes the region from a.a. 224 to 237, located in the extracellular domain of (P)RR³³, which detects both FL (P)RR and NTF. The anti-ATP6AP2 antibody revealed that (P)RR is consistently expressed in both cytoplasm and nucleus in four different cell lines (Fig. 4a). In contrast, anti-ATP6AP2 antibody recognizing the extracellular domain of (P)RR found that (P)RR expression is limited in the cytoplasm (Fig. 4b). These findings suggest that CTF of (P)RR is expressed in the nucleus. To further investigate the actual localization of CTF of (P)RR in the nucleus, we separated the cytoplasmic, soluble, and insoluble nuclear fractions from whole-cell lysates. In two different human PDAC cell lines, FL (P)RR is present in both the whole-cell lysates and the cytoplasmic fraction, whereas the CTF of (P)RR is dominant in the insoluble nuclear fraction occupied by nuclear lamina and chromatin-binding proteins using anti-ATP6AP2 antibody recognizing from a.a. 146 to 350 (Fig. 4c).

**Fig. 4: Intracellular localization of domains of (P)RR.**

Downregulation of genomic stability pathways

To elucidate the molecular mechanism responsible for the genomic instability induced by aberrant (P)RR expression, we performed LC-MS/MS analysis in the fraction of insoluble nucleus extracted from Mock- and (P)RR-expressing HPDE-1/E6E7 cells. From this analysis, we detected differences in expression of a total of 14,583 peptides. We implemented the global permutation-based false discovery rate (FDR) approach in Perseus³⁴ and 2340 peptides with FDR = 0.05 and minimal fold change (S0) = 0.5 were considered as significantly differentiated peptides (Supplementary Fig. 4a, b). Based on the fact that CTF of (P)RR was expressed in the insoluble nucleus containing chromatin-binding protein, further analyses were performed by using biological information regarding chromatin and/or DNA binding as Gene Ontology (GO) terms³⁵ (Supplementary Data 4). Using significant peptides filtered by GO terms, we also performed Ingenuity Pathway Analysis (IPA) to identify related diseases, and each molecular function and canonical pathways affected by the increase of (P)RR expression. Regarding downregulated molecules, cancer was identified as top of related diseases and it was not expected from the information of upregulated molecules (Fig. 5a and Supplementary Fig. 4c). By analyses of upregulated and downregulated molecules, it was revealed that (P)RR overexpression substantially affects gene expression and DNA replication, recombination and repair (Fig. 5b and Supplementary Fig. 4d). The significant canonical pathways responsible for “Granzyme A signalling”, “estrogen receptor signalling”, “nucleotide excision repair (NER)” and “glucocorticoid receptor signalling” were identified by analysis of the upregulated molecules (Supplementary Fig. 4e). On the other hand, different genome stability pathways such as “cell cycle control of chromosomal replication”, “base excision repair (BER)”, “DNA double-strand break repair by nonhomologous end joining (NHEJ)” and “telomere extension by telomerase” pathways (Fig. 5c, d) were identified with high statistical significance under IPA in the downregulated molecules. As these pathways are marked as main pathways implicated in genomic instability³⁶, we also examined molecular functions composed of the downregulated molecules by using cells with the deletion of each domain of (P)RR (Fig. 5e and Supplementary Fig. 5a). Besides the inactivation of the components responsible for DNA damage response such as H2AX (Ser.139) by (P)RR overexpression (Supplementary Fig. 5b), we also confirmed significant downregulation of MCM3, PCNA, PARP1 and Ku80 encoded by XRCC5 in both HPDE-1/E6E7 and HEK293 cells with FL(P)RR and (P)RR-⊿N at six-passage (Fig. 5f and Supplementary Fig. 5c). Even in 20-passage Mock cells having undergone a substantial cell division, expression of these molecules was maintained (Supplementary Fig. 5d). On the other hand, Wnt components such as pLRP6 and active β-catenin were upregulated in cells with FL(P)RR and (P)RR-⊿C (Fig. 5g). Cell proliferative ability was also significantly increased in these cells (N = 3 for each; one-way ANOVA; P < 0.05; Fig. 5h). Collectively, these results indicate that downregulation of molecules involved in genomic stability mediated by CTF of (P)RR is not associated with the increased number of cell division through NTF of (P)RR. We also conducted DNA fibre assay to determine the progression of individual replication forks and fork stalling. Compared to Mock-expressing HPDE-1/E6E7 cells, significantly slower fork rate and increased replication fork stalling (Mock: 0%; FL(P)RR: 19%; (P)RR-⊿C:0% (P)RR-⊿N: 20%) were detected in both FL(P)RR- and (P)RR-⊿N-expressing HPDE-1/E6E7 cells, which is consistent with the data from HEK293 cells with deletion mutants of (P)RR (N = 100 for each; one-way ANOVA; P < 0.0001; Fig. 5i and Supplementary Fig. 6).We also determined the level of DNA damage including single-and double-strand breaks by comet assay³⁷. Data showed that the percentage of distinctive DNA tails was significantly higher in cells with FL(P)RR and (P)RR-⊿N (N = 100 for each; one-way ANOVA; P < 0.0001; Fig. 5j and Supplementary Fig. 7). These results demonstrate that aberrant CTF expression of (P)RR leads to DNA replication stress and defects of DNA repair capacity. We also implemented Flow-FISH to measure the length of telomeres³⁸, which is considered to be an indicator of the early carcinogenesis of PDAC³⁹. Data showed that increased (P)RR expression reduces telomere length by 22% (N = 3 for each; Mann–Whitney U test; P < 0.05; Fig. 5k and Supplementary Fig. 8). Overall, these combined analyses revealed that aberrant expression of (P)RR leads to failure of coordination of different genomic stability pathways.

**Fig. 5: Dysfunction of genomic stability pathways by aberrant (P)RR expression in HPDE-1/E6E7 cells.**

Direct molecular binding of (P)RR with SMARCA5

To investigate the genome integrity network responsible for transcriptional regulation, DNA replication, DNA repair and telomere maintenance, we performed a network analysis of IPA with filtered significant peptides under aberrant (P)RR expression. These analyses successfully resulted in the identification of four different functional networks with significant Ingenuity scores, which were related to molecular functions such as gene expression, cellular assembly and organization, and DNA replication, recombination and repair (Fig. 6a and Supplementary Fig. 9 and Supplementary Data 4). These molecular networks can also be merged into a single molecular network through several common molecules (Fig. 6a and Supplementary Fig. 9 and Supplementary Data 4). Among the identified molecular networks, we focused on the network characterized by cellular assembly and organization, which also includes imitation switch (ISWI) and chromatin helicase DNA binding protein (CHD) chromatin remodelling complexes affecting histone 4 (Fig. 6a and Supplementary Data 4). Previous studies have shown that chromatin remodelling can coordinate the DNA accessibility of components involved in DNA-dependent processes by a change of the epigenomic landscape⁴⁰. These lines of evidence, combined with the present substantial data, strongly suggest that (P)RR plays an important role in regulation of the chromatin remodelling complex. Throughout the whole molecular network, components of three different chromatin remodelling complexes, namely, ISWI, CHD and inositol 80 requiring (INO80), were also included (Fig. 6b). Moreover, SMARCA5 plays a pivotal role as an ATPase in this complex and undertakes molecular interactions with several components of other chromatin remodelling complexes^{41,42,43,44,45,46,47,48}, suggesting that SMARCA5 is a central player in this molecular network (Fig. 6b). In (P)RR-expressing HPDE-1/E6E7 and HEK293 cells, the upregulation of SMARCA5 was confirmed by both LC-MS/MS analysis and western blotting (Fig. 6c and Supplementary Fig. 10a). Furthermore, MCM3, PCNA, PARP1 and Ku80 as the components responsible for genome stability pathways, were downregulated in cells with aberrant SMARCA5 expression (Fig. 6d and Supplementary Fig. 10b). Similar changes were observed in cells with aberrant (P)RR expression (Fig. 5f). To explore whether (P)RR has a direct molecular interaction with SMARCA5, we performed co-immunoprecipitation using the insoluble nucleus fraction containing CTF of (P)RR. The data showed that endogenous (P)RR undertook direct molecular binding with endogenous SMARCA5 (Fig. 6e and Supplementary Fig. 10c). Treatment with two different SMARCA5 siRNAs rescued the expression of molecules responsible for genomic stability pathways in (P)RR-expressing cells (Fig. 6f and Supplementary Fig. 10d). Collectively, these results demonstrate that aberrant (P)RR expression increases SMARCA5 expression through direct molecular interaction, which results in the downregulation of several genomic stability pathways. In conclusion, our substantial data strongly indicate that aberrant (P)RR expression induces genomic instability and is an essential molecular mechanism for early carcinogenesis of PDAC (Fig. 7).

**Fig. 6: Direct molecular binding of (P)RR with SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily a, member 5 (SMARCA5).**

**Fig. 7: Possible molecular mechanism of genomic instability induced by aberrant (P)RR expression.**

Discussion

The present study demonstrates that aberrant (P)RR expression directly induces genomic instability and tumour-forming ability in HPDE cells. The increase of (P)RR expression also upregulates SMARCA5 through a direct molecular interaction, which results in the dysfunction of DNA maintenance, such as DNA replication, DNA repair and telomere maintenance. The data reveal that inappropriate augmentation of (P)RR expression is the fundamental molecular mechanism responsible for the early carcinogenesis of (P)RR in PDAC.

Our previous study showed that the increase of (P)RR expression synchronizes with the appearance of atypical nuclei observed in PanIN-2 of human PDAC tissues⁷. In the present study, (P)RR-expressing HPDE-1/E6E7 and HPDE-6/E6E7 cell populations were mainly composed of significantly larger cells containing atypical nuclei with distinctive nuclear bodies, much variable and larger nuclear area, multinucleate as well as abnormal chromosomes, all of which are biological characters of cancer. Diverse atypical nuclei observed in (P)RR-expressing cell populations implies that future studies with genomic analysis at single-cell level will explain the detailed status of intra-tumoral heterogeneity.

Whole-genome sequencing has revealed that stable (P)RR overexpression induces large numbers of point mutations and SVs including driver genes defined by COSMIC, but does not increase indels. These results indicate that stable (P)RR overexpression induces genomic instability responsible for the generation of tumour heterogeneity. Several studies have shown that increased SVs and somatic mutations are frequently observed in PDAC^4,5. Furthermore, SVs associated with the appearance of driver genes of PDAC and the increase of total somatic mutations were found in PanIN^5,49. Additionally, PDAC patients with large number of SVs called as “unstable subtype” were characterized by more aggressive behaviour, which is related to refractory^4,5. Indeed, (P)RR expression was increased with severe stage in TNM classification in tissues of PDAC patients⁶. Taken together, these results suggest that sequential elevation of (P)RR expression contributes not only to carcinogenesis, but also the augmentation of aggressiveness and refractory representing a malignancy of PDAC patients through genetic aberration.

In the present study, (P)RR-expressing HPDE-1/E6E7 cell population exhibited tumour-forming ability. Although the explosive cell population growth was not observed, owing to the absence of KRAS codon 12 mutation, (P)RR-expressing cells exhibited atypical nuclei with chromosomal abnormalities of bridge and fusion generated by telomere dysfunction³¹. These findings are consistent with the concept that (P)RR-expressing HPDE-1/E6E7 cell populations undergo a pre-cancerous state and have the potential to progress towards becoming cancerous. Because theoretical analyses have shown that gene alterations accumulate in proportion to the number of cell divisions^50,51 and the level of acquired neutral mutations⁵², future studies with long-term cell culture will be needed until the successful detection of driver mutations of PDAC patients in (P)RR-expressing HPDE-1/E6E7 cell population.

The present study showed that FL(P)RR and/or NTF were consistently expressed in the cytoplasm, while CTF was dominantly located in the nucleus composed of nuclear lamina and chromatin-binding protein in both human PDAC cell lines and (P)RR-expressing HPDE-1/E6E7 cells. Previous studies showed that FL(P)RR and/or NTF were localized in the cytoplasm of COS-7 and MEF cells^25,53. Similar to human PDAC cell lines, the information from the database of The Human Protein Atlas (https://www.proteinatlas.org)⁵⁴ showed that (P)RR is expressed in both cytoplasm and nucleus in several cancer cell lines when using the antibody recognizing all the domains of (P)RR, which further supports our hypothesis that CTF of (P)RR is involved in genomic stability.

Our data reveal that aberrant (P)RR expression affects gene expression, DNA replication, recombination and repair, and induces a failure in the coordination of these genomic stability pathways. Downregulation of molecules responsible for genomic stability was observed in cells with FL(P)RR and (P)RR-⊿N. Furthermore, DNA fibre and comet assays indicate that CTF of (P)RR plays a critical role in the protection of DNA. In connection with the defects of DNA repair capacity, inactivation of DNA damage response leads to the failure of anti-tumourigenesis barrier function⁵⁵. DNA replication stress is induced by the reduction of minichromosome maintenance complex component (MCM)2-7 constituting the core of the replicative DNA helicase⁵⁶. Thus, it is possible that the increase in DNA replication stress is involved in the downregulation of components of MCM complex induced by aberrant (P)RR expression. It has also been shown that DNA replication stress leads to the accumulation of DNA lesions and induces striking chromosomal instability in cancer cells in the absence of mitotic dysfunction⁵⁷. Interestingly, our data have revealed that aberrant (P)RR expression induces DNA replication stress and SVs including several dozens of large deletions, suggesting DNA replication stress is not due to mitotic dysfunction. Namely, domain of (P)RR regulating genomic stability including DNA replication is mediated by CTF of (P)RR, which is independent of NTF of (P)RR induced cell proliferation. The scarcity of indels observed in the mutational landscape of stable (P)RR-overexpressing cells also supports the concept that DNA replication stress is not mediated by cell proliferation. Since loss of function of BER enhances the somatic mutation rate⁵⁸, massive SVs and elevated rate of somatic mutations detected by whole-genome sequencing will be the consequence of the above genetic change induced by (P)RR overexpression.

Dysfunction of NHEJ leads to failure of regulation of the correct length of telomeres and of protection of their ends⁵⁹. In association with the reduction of Ku80 expression⁶⁰, shortened telomeres are observed as an initial genetic change, which are found in more than 90% of PDAC tissues^39,61,62. Consistent with these pathological analyses in PDAC patients, the present study reveals that aberrant (P)RR expression reduces the telomere length associated with the downregulation of XRCC 5 encoding Ku80, which is associated with complex SVs. These findings support our hypothesis that an increase of (P)RR expression is an essential molecular mechanism behind the early carcinogenesis in PDAC. In this context, our data previously indicated that plasma-soluble (P)RR is a potential biomarker to identify patients with PDAC from an early stage⁷.

We have detected that aberrant (P)RR expression upregulates SMARCA5, which is the catalytic subunit of ATPase, to form ISWI chromatin remodelling complex coordinating the access of DNA binding proteins to DNA⁶³. By using information from The Human Protein Atlas⁵⁴, we have confirmed that SMARCA5 is aberrantly expressed in over 80% of PDAC patients. In SMARCA5-expressing cells, several components of the DNA replication, DNA repair and telomere maintenance machinery were markedly downregulated, which coincides with the results of (P)RR-expressing cells. In the present study, we have demonstrated a direct molecular binding between (P)RR and SMARCA5. Furthermore, reduction in SMARCA5 rescued the expression of molecules responsible for genomic stability in (P)RR-expressing cells. These data support the hypothesis that the upregulation of SMARCA5 is induced by aberrant (P)RR expression through their direct molecular interaction, which plays an important role in generating genetic evolution of PDAC. Our data also showed that (P)RR overexpression reduces PARP1 expression through the upregulation of SMARCA5. To accomplish DNA damage responses followed by the NHEJ repair pathway, PARP1 poly ADP-ribosylates (PARylates) histone tails, resulting in the promotion of chromatin relaxation and nucleosome eviction from DNA^64,65. These processes allow the recruitment of several chromatin remodellers, such as SMARCA5 and CHD4, through the binding to PAR, which further relaxes chromatin to facilitate DNA repair, such as NHEJ. Thus, reduction in PARP1 expression induced by SMARCA5 overexpression may prevent not only the relaxation of chromatin, but also the recruitment of SMARCA5, followed by limiting the access of DNA repair proteins to chromatin.

Although the clear genomic instability is intrinsically linked to significant alterations in apoptosis control⁶⁶, cell proliferative ability was not affected in (P)RR-expressing cells. It has been shown that NTF of (P)RR is actually a component of the Wnt receptor complex¹². The data from the present study also indicate that NTF of (P)RR contributes to cell proliferation through the activation of Wnt/β-catenin signalling pathway. Other investigators have also indicated that Wnt signalling in cooperation with mitogen-activated protein kinase activation promotes the proliferation of established PanIN lesions⁶⁷. Furthermore, it has also been shown that aberrant (P)RR expression contributes to activation of the PI3K/Akt signalling pathway⁶. Collectively, these findings suggest that the orchestrated activities of different signalling pathways promote maintenance of the proliferative ability of (P)RR-expressing cells, despite marked genomic instability.

In conclusion, the present study demonstrates that aberrant (P)RR expression induces genomic instability by an increase in SMARCA5 expression through a direct molecular interaction. These data indicate that inappropriate augmentation of (P)RR expression contributes to the evolution of PDAC.

Methods

Cell lines

Immortalized HPDE-1/E6E7²³ and HPDE-6/E6E7²⁴ cells were cultured in Hu-Media KG2 (Kurabo, Osaka, Japan; catalogue #KK-2150S), which were gifted from Dr. Furukawa. In addition, HEK293 cells were cultured in DMEM (Sigma-Aldrich, St. Louis, MO, USA; catalogue #D5796) supplemented with 10% FBS, penicillin and streptomycin. Both media containing 400 µg/mL G418 (Sigma-Aldrich; catalogue #A1720) as an antibiotic were used to culture successfully transfected cells. PK-1, PANC-1 and MiaPaCa-2 of human PDAC cell lines and Human T-cell leukaemia 1301 cells were cultured in RPMI-1640 (Sigma-Aldrich; catalogue #R8758) supplemented with 10% FBS, penicillin and streptomycin. These cell lines were maintained at 37 °C under 5% CO₂/95% air in a humidified incubator. HEK293 was drawn from stocks at Department of Pharmacology, Faculty of Medicine, Kagawa University. PK-1 was originally from Institute of Development, Aging and Cancer (IDAC). PANC-1 and MiaPaCa-2 were purchased from American Type Culture Collection (ATCC). 1301 were from European Collection of Cell Cultures (ECACC). The sources of cell lines were also listed in Supplementary Data 5. All the cell lines used in this study have been tested for mycoplasma by MicoAlert (Lonza, Tokyo, Japan; catalogue #BWLT07). No commonly misidentified lines were used in the study.

Vector construction

pOTB7 vector inserted with human ATP6ap2 was obtained from GE Healthcare (Chicago, IL, USA; catalogue #6575732). A DNA fragment corresponding to human ATP6ap2 (1050 bp without a stop codon) encoding (P)RR was inserted into the restriction sites of BamHI and AgeI within the mammalian expression plasmid pEB Multi-Neo TARGET tag-C (Wako, Osaka, Japan; catalogue #165-26521) to generate stable (P)RR-expressing HPDE-1/E6E7, HPDE-6/E6E7 and HEK293 cells. Human ATP6ap2 inserted into pcDNA 3.0 tagged with 10His²⁵ was also used for making stable and non-replicative transient (P)RR-expressing cells. Plasmid pEB Multi-Neo TARGET tag-C were used to construct not only human (P)RR with the full length [FL (P)RR], but also ⊿NTF of (P)RR [amino acids (a.a.) 304–350; (P)RR-⊿N] and ⊿CTF of (P)RR [a.a. 17–275; (P)RR-⊿C]. The sequence integrity of all inserts was confirmed by Sanger DNA sequencing. The open reading frame of human SMARCA5 tagged with Myc-DDK (RC203775) was also purchased from ORIGENE (Rockville, MD, USA).

Plasmid and siRNA transfection

In accordance with the manufacturer’s instructions, FL(P)RR-, (P)RR-⊿N-, (P)RR-⊿C- or SMARCA5-expressing vector or an empty vector was transfected into HPDE-1/E6E7, HPDE-6/E6E7 and HEK293 cells using Lipofectamine 3000 (Thermo Fisher Scientific; catalogue #L3000008). Using Lipofectamine RNAiMAX (Thermo Fisher Scientific; catalogue #13778075), SMARCA5 Stealth RNAi™siRNA was transfected into (P)RR-expressing cells according to the recommended protocol. The sequences used to generate SMARCA5 Stealth RNAi™ siRNA #1 were as follows: 5′-GGA GGC UUG UGG AUC AGA AUC UGA A-3′and 5′-UUC AGA UUC UGA UCC ACA AGC CUC C-3′. The sequences used to generate SMARCA5 Stealth RNAi™ siRNA #2 were as follows: 5′-CAG GGA AGC UCU UCG UGU UAG UGA A-3′ and 5′-UUC ACU AAC ACG AAG AGC UUC CCU G-3′. For the scrambled siRNA, Stealth RNAi™ siRNA Negative Control Med GC (Thermo Fisher Scientific; catalogue #12935-300) was used.

Confirmation of gene transfection

(P)RR fused to Target tag (168 bp) and to 10His tag (244 bp) was detected by PCR. The primer sequences used are listed in Supplementary Data 5. The PCR was performed using Takara Ex Taq (Takara Bio; catalogue #RR001A). PCR conditions were as follows: 94 °C for 2 min, followed by 40 cycles of denaturation at 98 °C for 10 s, annealing at 64 °C for 30 s and extension at 72 °C for 1 min. The final extension was then performed at 72 °C for 5 min. PCR products were visualized by gel electrophoresis. The detection of FL(P)RR, (P)RR-⊿N and (P)RR-⊿C was confirmed using Simple Western™ System (ProteinSimple, San Jose, CA, USA), in accordance with previous reports⁶⁸ and the manufacturer’s instructions. The protein concentration in each sample was set as 2 µg/µL and was serially diluted to detect the target band. Separation electrophoresis and immunodetection were performed automatically. The detection of deletions of the (P)RR domain was performed using anti-ATP6ap2 antibody having an immunogen corresponding to a region within a.a.146 and 350 (Sigma-Aldrich; catalogue #SAB2702080).

Cellular atypia

We evaluated the cell area of HPDE-1/E6E7 and HPDE-6/E6E7 cells expressing Mock or (P)RR using Image J. Papanicolaou stain was also performed. Multinucleated cells were evaluated by visual observation and the nuclear area was measured in Image J using Mock- and (P)RR-expressing HPDE-1/E6E7and HPDE-6/E6E7 cells.

In vivo transplantation

Approval for this experiment was obtained from the Animal Experimentation Ethics Committee of Kagawa University. Five-week-old male BALB/c immunodeficient mice (nu+/nu+) (CLEA, Tokyo, Japan) were used for the implantation experiments. Three-dimensional spheroids were prepared from HPDE-1/E6E7 cells expressing either Mock or (P)RR, in accordance with a previous report⁶⁹. In all, 5 × 10³ cells from each group were seeded onto a V-bottomed 96-well plate (Sumitomo Bakelite Co. Ltd., Tokyo, Japan; catalogue #MS-9096V) with 150 μL of culture medium in each well and cultured for four days. Then, 20 aggregates prepared from HPDE-1/E6E7 cells expressing either Mock or (P)RR were implanted into the renal subcapsules of immunodeficient mice. Five weeks later, these animals were sacrificed and the kidney sections including implanted spheroids were collected. After embedding in paraffin, the sectioned samples were stained with haematoxylin and eosin.

Direct cell counting

We performed a count of the total number of HPDE-1/E6E7 cells expressing either Mock or the deletion of each domain of (P)RR over 18 days. The cells were treated with Accutase (Merck Millipore, Billerica, MA, USA; catalogue #SCR005). They were then re-suspended in PBS after centrifugation. Cell suspension was stained with 0.4% trypan blue stain solution to evaluate the number of living cells. Total cell number per millilitre was measured using a Countess® Automated Cell Counter (Thermo Fisher Scientific; catalogue #C10227).

DNA extraction

To collect DNA, we prepared HPDE-1/E6E7 cells expressing either Mock or (P)RR. The genomic DNA from each cell was then extracted using the QIAGEN Blood & Cell Culture Kit (Qiagen; catalogue #13362).

PCR and DNA sequencing for KRAS and CDKN2A

For the detection of somatic mutations in KRAS and CDKN2A, primers were used for PCR amplification, as described previously⁷⁰. The primer sequences are listed in Supplementary Data 5. Using Takara Ex Taq, initial denaturation was performed at 94 °C for 2 min, followed by 30 cycles of denaturation at 98 °C for 10 s, annealing at 52 °C for KRAS and at 65 °C for CDKN2A for 30 s, and extension at 72 °C for 1 min. Then, the final extension was performed at 72 °C for 5 min. PCR products were visualized by gel electrophoresis. BigDye Terminator v3.1 Cycle Sequencing Kit (Thermo Fisher Scientific; catalogue #4336917) and BigDye Terminator Purification Kit (Thermo Fisher Scientific; catalogue #4376484) were used to sequence the PCR products. The DNA sequence was evaluated by ABI PRISM 3100 Genetic Analyzer (Thermo Fisher Scientific), based on the manuals provided by the manufacturer.

Immunofluorescence of (P)RR

PK-1, PANC-1, MiaPaCa-2 cells and (P)RR-expressing HPDE-1/E6E7 cells were grown on chamber slides (Matsunami, Osaka, Japan; catalogue #SCS-002). The cells were fixed in 4% paraformaldehyde phosphate-buffered solution (Wako; catalogue #163-20145) at room temperature for 5 min. After washing with PBS containing 0.1% Tween 20, the cells were then incubated for 20 min in blocking solution containing fetal bovine serum. The cells were incubated at 4 °C overnight with either Anti-ATP6ap2 antibody produced in a rabbit as an immunogen corresponding to the region within a.a. 146 and 350 (Sigma-Aldrich; catalogue #SAB2702080) or a.a. 224 and 237³³. After washing with PBS containing 0.1% Tween 20, cells were incubated at room temperature for 2 h with Goat anti-rabbit IgG (H + L) highly cross-adsorbed secondary antibody, Alexa Fluor anti-rabbit 488 (Thermo Fisher Scientific; catalogue #A11034), to detect (P)RR expression labelled by different Anti-ATP6ap2 antibodies. The nuclei were stained by H33258 (Sigma-Aldrich; catalogue #B2883). Fluorescence images were obtained using Olympus FSX 100 (Olympus, Tokyo, Japan).

Western blot analysis

Measurement of protein concentration after lysis of cells and protein extraction were performed by Bradford protein assay⁷. Total protein extracts (30 µg) were electrophoretically separated using polyacrylamide gels with SDS ranging from 10% to 14% and transferred onto nitrocellulose membranes. For protein expression, we used blocking buffer and secondary antibodies coupled to infrared dyes required for the Odyssey scanner (LI-COR, Lincoln, NE, USA)⁷. The period for incubation is 1 h at room temperature in each process. The primary and secondary antibodies used are described in Supplementary Data 5.

Protein extraction from insoluble nuclear fraction

LysoPure™ Nuclear and Cytoplasmic Extractor Kit (Wako; catalogue #295-73901) allowed us to extract cytoplasmic, soluble and insoluble nuclear fractions to elucidate the intracellular localization of domains of (P)RR. In accordance with the manufacturer’s instructions, the insoluble nuclear fraction was extracted using SDS lysis buffer and sonication after the extraction from cytoplasmic and soluble nuclear fractions.

DNA fibre assay

To evaluate the DNA replication stress upon aberrant (P)RR expression, we performed DNA fibre assay. Cells were pulse-labelled with 100 μM CldU (Sigma-Aldrich; catalogue #C6891) for 20 min, and then with 100 μM IdU (Tokyo Chemical Industry, Tokyo, Japan; catalogue #I0258) for 20 min. After cells had been lysed, the cell suspension was spread on a slide glass. Once dried, the DNA spread was fixed in a 3:1 solution of methanol-acetic acid, pre-chilled 70% ethanol and methanol. After washing with PBS, DNA was denatured with 2.5 N HCl for 30 min. Samples were rinsed with PBS and incubated with the following antibodies: anti-BrdU rat IgG and anti-BrdU mouse IgG in 1% BSA. The details of the primary antibodies are described in Supplementary Data 5. After incubation for 1 h at room temperature, the slides were washed three times for 3 min in PBS containing 0.05% Tween 20. The slides were incubated with the following secondary fluorescent antibodies: Alexa anti-mouse 488 (Thermo Fisher Scientific; catalogue #A11001) and Alexa-anti rat 594 (Thermo Fisher Scientific; catalogue #A11007) for 1 h at room temperature. After washing with PBS containing 0.05% Tween 20, slides were mounted using Fluoromount™ (Sigma-Aldrich; catalogue #C4680). Signals were measured using Image J.

Detection of DNA damage

The DNA repair capacity upon aberrant (P)RR expression was measured by comet assay³⁷. For this assay, the OxiSelect™ Comet Assay Kit (Cell Biolabs, Inc., San Diego, CA, USA; catalogue #STA-350) was used. The “tail” resulting from the damaged DNA was separated from intact DNA by single-cell gel electrophoresis. Cells were resuspended at 1 × 10⁵ cells/mL in ice-cold PBS. Cell suspension was combined with Comet Agarose at a 1:10 ratio (v/v) and loaded onto the OxiSelect™ Comet Slide. Under dark conditions, embedded cells were treated for 30 min at 4 °C in lysis buffer and then an alkaline solution to relax and denature the DNA. Samples were electrophoresed to detect single-and double-stranded DNA damage by using alkaline electrophoresis buffer. After rinsing the slides with distilled water, they were immersed in 70% ethanol. DNA was stained with Vista Green DNA Dye. Tail DNA intensity (%) was calculated by OpenComet⁷¹.

Telomere length measurement by Flow-FISH

Telomere length was measured using Telomere PNA Kit/FITC (DAKO, Glostrup, Denmark; catalogue #K5327). Telomere length of the HPDE-1/E6E7 cells expressing either Mock or (P)RR was determined. Human T-cell leukaemia 1301 cells (ECACC, Salisbury, UK; catalogue #EC01051619-G0) characterised by tetraploidy and long telomeres were used as an internal standard. Test and control cells were mixed at a ratio of 1:1 and a total of 4 × 10⁶ cells was resuspended in 300 µL of hybridization solution with or without a fluorescein isothiocyanate (FITC)-conjugated telomere probe. DNA was denatured for 10 min at 82 °C. In situ hybridization was performed at room temperature under dark conditions. Cells were rinsed with washing solution and heated for 10 min at 40 °C. They were then resuspended in 0.5 mL of DNA staining solution containing propidium iodide and RNase A and incubated for 3 h at 4 °C in the dark. Samples were analysed by flow cytometry. FlowJo (Tomy Digital Biology Co., Ltd., Tokyo, Japan) was used for analysis and relative telomere length (RTL) was calculated based on mean fluorescence intensity (MFI)⁷².

Coimmunoprecipitation

For coimmunoprecipitation, we used the insoluble nuclear fractions in HEK293 and HPDE-1/E6E7 cells. A total of 50 μL of prewashed Dynabeads Protein G (Thermo Fisher Scientific; catalogue #10003D) was coupled with 10 μg of anti-h(P)RR antibodies, anti-SMARCA5 antibodies or nonspecific rabbit IgG diluted in 200 μL of PBS with Tween-20 for 1 h at room temperature under the rotator. The information for antibodies used are described in Supplementary Data 5. One milligram of protein was incubated with antibody conjugated with Dynabeads for 2 h at 4 °C. For immunoblotting, equal amounts of immunocomplexes or lysates were utilized and resolved by SDS-PAGE.

Whole-genome sequencing and mutation calling

In six-passage HPDE-1/E6E7 cells expressing stable Mock and (P)RR using pEB Multi-Neo TARGET tag-C, DNA was also quantified using the Quant-iT dsDNA BR Assay Kit (Thermo Fisher Scientific; catalogue #Q33120) to produce a whole-genome library in accordance with manufacturer’s recommendations. For PCR-Free libraries, the TruSeq DNA PCR-Free LT Library Prep Kit (Illumina, San Diego, CA, USA; catalogue #FC-121-9006DOC) was used. In accordance with the manufacturer’s instructions (Part #15036187 Rev. D, June 2015), we prepared whole-genome libraries as described below. DNA (1 µg) was diluted to 20 ng/µL using resuspension buffer before DNA fragmentation. DNA was fragmented to ~350 bp using Acoustic solubilizer (Covaris, Woburn, MA, USA). DNA fragment ends were repaired using End Repair Mix2. Following the end repair of DNA fragments, we performed size selection using Agencourt AMPure XP (Beckman Coulter, catalogue #A63880) to select an appropriate library size. A single “A” nucleotide was added to the 3′ ends of the blunt fragments to prevent them from ligating with each other during the process of adaptor ligation and size-selected libraries were then ligated with indexed adaptors. The quality of the final whole-genome libraries was evaluated using the Agilent 2100 BioAnalyzer (G2940CA).

In accordance with the cBot User Guide Rev. L (Part #15006165), whole-genome libraries were prepared for cluster generation by cBot. To analyse sequences on the next-generation sequencer, the flow cells were clustered on the cBot using HiSeq PE Cluster Kit v4 cBot (Illumina; catalogue #PE-401-4001). DNA libraries were analysed on the Illumina HiSeq 2500 instrument using HiSeq SBS Kit v4-H (catalogue #FC-401-4002) to perform paired-end 125-bp sequencing. In HPDE-1/E6E7 cells expressing transient Mock and (P)RR and HPDE-1/E6E7 cells without transfection, libraries were prepared using the TruSeq^TM DNA PCR-Free Library Preparation Kit (Illumina; catalogue #FC-121-3001). Cluster generation and sequencing were prepared on a Novaseq 6000 system using Novaseq 6000 S2 Reagents (Illumina; catalogue #200012860). Paired-end 150-bp sequencing was performed. The coverage was set to 30x for all the samples.

Read sequences were mapped by Burrows-Wheeler Aligner (BWA) to the human reference genome (GRCh37)⁷³. Possible PCR duplicated reads were removed using SAMtools and an in-house program⁷⁴. Point mutations and short indels were identified with variant allele frequency using MCV pipeline²⁶. Structural variations (SVs) were detected by mapping information. Read pairs with inconsistent mapping patterns were identified, and SVs supported by ≥4 inconsistent read pairs were called. Possible mapping errors were removed based on re-alignment. The details of the mutation calling methods are described in Fujimoto et al.²⁶. We used HPDE-1/E6E7 cells without transfection as the reference and mutations were detected by comparing each Mock- and (P)RR-overexpressing HPDE-1/E6E7 cells against the reference. Since mutations should have accumulated in HPDE-1/E6E7 cells before transfection, we removed common mutations detected in 2 or more samples.

Protein identification using nano LC-MS/MS

We performed nanoscale liquid chromatography with tandem mass spectrometry (LC-MS/MS) to elucidate the differences of whole protein expression between Mock- and (P)RR-expressing HPDE-1/E6E7 cells. Pierce™ Mass Spec Sample Prep Kit for Cultured Cells (Thermo Fisher Scientific; catalogue #84840) allowed us to perform the reduction, alkylation, acetone precipitation and trypsin digestion using proteins extracted from the insoluble nuclear fraction of Mock and (P)RR-expressing HPDE-1/E6E7 cells, respectively. The peptides were loaded onto the LC system (EASY-nLC 1000; Thermo Fisher Scientific, San Jose, CA, USA) equipped with a trap column (Acclaim PepMap 100 C18 LC column, 3 μm, 75 μm ID × 20 mm; Thermo Fisher Scientific) equilibrated with 0.1% formic acid and eluted with a linear acetonitrile gradient (0%–35%) at a flow rate of 300 nL/min. The eluted peptides were separated on the column (EASY-Spray C18 LC column, 3 μm, 75 μm ID × 150 mm; Thermo Fisher Scientific) with a spray voltage of 2 kV (ion transfer tube temperature: 275 °C). By using MS (Orbitrap Fusion ETD MS; Thermo Fisher Scientific), the peptide ions were detected in the data-dependent acquisition mode with the installed Xcalibur software (version 4.0; Thermo Fisher Scientific). Full-scan mass spectra were acquired in the MS over 375–1500 m/z at a resolution of 120,000. The most intense precursor ions were selected for collision-induced fragmentation in the linear ion trap under normalized collision energy of 35%. Dynamic exclusion was employed within 60 s to prevent repetitive selection of peptides.

MS data analysis

The MS/MS searches were carried out using MASCOT (Version 2.6.1; Matrix Science, London, U.K.) and SEQUEST HT search algorithms against the SwissProt Homo sapiens protein database (2017-05) using Proteome Discoverer (PD) 2.1 (Version 2.1.1.21; Thermo Scientific). The search algorithms in this study were spectrum selector, Mascot, SEQUEST HT search nodes, percolator and ptmRS nodes. Carbamidomethyl cysteine was set as a fixed modification and oxidation of methionine, carbamidomethylation of histidine, lysine, peptide N-terminus and acetylation of protein N-terminus were considered as variable modifications. MS and MS/MS mass tolerances were set to 10 ppm and 0.6 Da, respectively. Trypsin was specified as the protease and a maximum of two missed cleavages were allowed. The target-decoy database search results used for calculation of the false discovery rate (FDR) was set at 0.01.

Bioinformatic analysis

Label-free quantification (LFQ) was also processed with PD2.1 using precursor ion area detector mode. For differential analysis of the relative abundances of peptides between samples, Perseus³⁴ was used. The results were filtered using the following criteria. We utilized the peptides including three valid values in at least one group to ensure reliability of the data. Normalization of intensities was performed by subtracting the median of each sample and missing values were imputed according to a normal distribution (width = 0.3, down-shift = 1.8).

A heat map based on LFQ was clustered using Euclidean distance to confirm the suitability of data analysis. A volcano plot was also depicted by a global permutation-based FDR approach implemented in Perseus. The level of significant cut-off value is determined based on a permutation-based FDR of 0.05 and S0 value of 0.5 as a minimal fold change. For pairwise comparison of groups, two-sample Student’s t-test (two-sided) was used. Ingenuity Pathway Analysis (IPA) was also utilized to evaluate the enrichment of functional analysis, canonical pathway and molecular network categories affected by aberrant (P)RR expression. Considering the evidence that CTF of (P)RR is expressed in the insoluble nuclear fraction, including chromatin-binding protein, significantly identified peptides that are also characterized by “chromatin” in GOCC (Gene Ontology Cellular Components) and/or “DNA-binding” in Gene Ontology Molecular Function (GOMF) were overlain onto the updated information developed from the Ingenuity Pathways Knowledge Base.

Statistics and reproducibility

At least two cell lines were used for several techniques, such as Papanicolaou stain, immunohistochemistry, western blot, DNA fibre assay, comet assay and coimmunoprecipitation to show reproducibility. We conducted these experiments to confirm data of HPDE-1/E6E7 cells presented in WGS and LC-MS/MS. Regarding the in vivo experiments, four of the kidneys were injected with (P)RR-expressing cells. All of the tissues formed by the injected (P)RR-expressing cells were composed of atypical cells. Results are expressed as mean ± SEM and beeswarm. Beeswarm was depicted by R (The R Foundation for Statistical Computing Platform). The Student’s t-test was used for the analyses of cell and nuclear area. Telomere lengths in Flow-FISH was tested by Mann–Whitney U test. We also used one-way ANOVA with Scheffe’s post hoc test to analyse the replication fork rates in the DNA fibre assay and DNA tails in the comet assay and with Tukey-Kramer’s post hoc test to analyse a cell proliferative ability in the deletion of each domain of (P)RR. Based on one hundred biological replicates in cell and nuclear area, DNA fibre assay and comet assay, cutoff was regarded as P < 0.0001. P < 0.05 was adopted in triplicate direct cell counting and Flow-FISH. The statistics are indicated in the specific “Results” and associated figure legends. All statistical analyses were performed using IBM SPSS Statistics 20 software (Armonk, NY, USA).

Reporting summary

Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability

All processed data and analyses generated during the current study are included in this article and its Supplementary Information files, including source data: Supplementary Data 1–5. For WGS data, Fastq files were deposited with the National BioScience Database Center (NBDC) as file accession No. JGAS00000000143. For MS data, RAW data, peak lists and result files have been deposited as accession No. PXD 010107 with the ProteomeXchange Consortium⁷⁵ via the jPOST⁷⁶ partner repository as JPST000440. All the data produced in this study are stored at Department of Pharmacology, Faculty of Medicine, Kagawa University and available from the corresponding author upon reasonable request.

References

Rawla, P., Sunkara, T. & Gaduputi, V. Epidemiology of pancreatic cancer: global trends, etiology and risk factors. World J. Oncol. 10, 10–27 (2019).
Article PubMed PubMed Central Google Scholar
Witkiewicz, A. K. et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat. Commun. 6, 6744 (2015).
Article CAS PubMed Google Scholar
Bailey, P. et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 531, 47–52 (2016).
Article CAS PubMed Google Scholar
Waddell, N. et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 518, 495–501 (2015).
Article CAS PubMed PubMed Central Google Scholar
Notta, F. et al. A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns. Nature 538, 378–382 (2016).
Article CAS PubMed PubMed Central Google Scholar
Arundhathi, A. et al. Prorenin receptor acts as a potential molecular target for pancreatic ductal adenocarcinoma diagnosis. Oncotarget. 7, 55437–55448 (2016).
Shibayama, Y. et al. (Pro)renin receptor is crucial for Wnt/beta-catenin-dependent genesis of pancreatic ductal adenocarcinoma. Sci. Rep. 5, 8854 (2015) .
Ichihara, A. & Yatabe, M. S. The (pro)renin receptor in health and disease. Nat. Rev. Nephrol. 15, 693–712 (2019).
Article PubMed Google Scholar
Nguyen, G. et al. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J. Clin. Invest. 109, 1417–1427 (2002).
Article CAS PubMed PubMed Central Google Scholar
Sakoda, M. et al. (Pro)renin receptor-mediated activation of mitogen-activated protein kinases in human vascular smooth muscle cells. Hypertens. Res. 30, 1139–1146 (2007).
Article CAS PubMed Google Scholar
Saris, J. J. et al. Prorenin induces intracellular signaling in cardiomyocytes independently of angiotensin II. Hypertension 48, 564–571 (2006).
Article CAS PubMed Google Scholar
Cruciat, C. M. et al. Requirement of prorenin receptor and vacuolar H+-ATPase-mediated acidification for Wnt signaling. Science 327, 459–463 (2010).
Article CAS PubMed Google Scholar
Rahman, A. et al. Antiproliferative effects of monoclonal antibodies against (Pro)Renin receptor in pancreatic ductal adenocarcinoma. Mol. Cancer Ther. 19, 1844–1855 (2020).
Article CAS PubMed Google Scholar
Kouchi, M. et al. (Pro)renin receptor is crucial for glioma development via the Wnt/beta-catenin signaling pathway. J. Neurosurg. 127, 819–828 (2017).
Article CAS PubMed Google Scholar
Wang, J. et al. (Pro)renin receptor promotes colorectal cancer through the Wnt/beta-catenin signalling pathway despite constitutive pathway component mutations. Br. J. Cancer 120, 229–237 (2019).
Article CAS PubMed Google Scholar
Kinouchi, K. et al. The (pro)renin receptor/ATP6AP2 is essential for vacuolar H+-ATPase assembly in murine cardiomyocytes. Circ. Res. 107, 30–34 (2010).
Article CAS PubMed Google Scholar
Forgac, M. Vacuolar ATPases: rotary proton pumps in physiology and pathophysiology. Nat. Rev. Mol. Cell Biol. 8, 917–929 (2007).
Article CAS PubMed Google Scholar
Kanda, A. et al. Atp6ap2/(pro)renin receptor interacts with Par3 as a cell polarity determinant required for laminar formation during retinal development in mice. J. Neurosci. 33, 19341–19351 (2013).
Article CAS PubMed PubMed Central Google Scholar
Buechling, T. et al. Wnt/Frizzled signaling requires dPRR, the Drosophila homolog of the prorenin receptor. Curr. Biol. 20, 1263–1268 (2010).
Article CAS PubMed Google Scholar
Hermle, T., Saltukoglu, D., Grunewald, J., Walz, G. & Simons, M. Regulation of Frizzled-dependent planar polarity signaling by a V-ATPase subunit. Curr. Biol. 20, 1269–1276 (2010).
Article CAS PubMed Google Scholar
Kanda, A., Noda, K. & Ishida, S. ATP6AP2/(pro)renin receptor contributes to glucose metabolism via stabilizing the pyruvate dehydrogenase E1 beta subunit. J. Biol. Chem. 290, 9690–9700 (2015).
Article CAS PubMed PubMed Central Google Scholar
Inagawa, Y. et al. A human cancer xenograft model utilizing normal pancreatic duct epithelial cells conditionally transformed with defined oncogenes. Carcinogenesis 35, 1840–1846 (2014).
Article CAS PubMed Google Scholar
Furukawa, T. et al. Long-term culture and immortalization of epithelial cells from normal adult human pancreatic ducts transfected by the E6E7 gene of human papilloma virus 16. Am. J. Pathol. 148, 1763–1770 (1996).
CAS PubMed PubMed Central Google Scholar
Ouyang, H. et al. Immortal human pancreatic duct epithelial cell lines with near normal genotype and phenotype. Am. J. Pathol. 157, 1623–1631 (2000).
Article CAS PubMed PubMed Central Google Scholar
Suzuki-Nakagawa, C. et al. Participation of the extracellular domain in (pro)renin receptor dimerization. Biochem. Biophys. Res. Commun. 444, 461–466 (2014).
Article CAS PubMed Google Scholar
Fujimoto, A. et al. Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer. Nat. Genet. 48, 500–509 (2016).
Article CAS PubMed Google Scholar
George, J. et al. Comprehensive genomic profiles of small cell lung cancer. Nature 524, 47–53 (2015).
Article CAS PubMed PubMed Central Google Scholar
Pitkanen, E. et al. Frequent L1 retrotranspositions originating from TTC28 in colorectal cancer. Oncotarget 5, 853–859 (2014).
Article PubMed PubMed Central Google Scholar
Bignell, G. R. et al. Signatures of mutation and selection in the cancer genome. Nature 463, 893–898 (2010).
Article CAS PubMed PubMed Central Google Scholar
Jankevicius, G. et al. A family of macrodomain proteins reverses cellular mono-ADP-ribosylation. Nat. Struct. Mol. Biol. 20, 508–514 (2013).
Article CAS PubMed PubMed Central Google Scholar
Gisselsson, D. et al. Telomere dysfunction triggers extensive DNA fragmentation and evolution of complex chromosome abnormalities in human malignant tumors. Proc. Natl Acad. Sci. USA 98, 12683–12688 (2001).
Article CAS PubMed PubMed Central Google Scholar
Cousin, C. et al. Soluble form of the (pro)renin receptor generated by intracellular cleavage by furin is secreted in plasma. Hypertension 53, 1077–1082 (2009).
Article CAS PubMed Google Scholar
Hirose, T. et al. Gene expression of (pro)renin receptor is upregulated in hearts and kidneys of rats with congestive heart failure. Peptides 30, 2316–2322 (2009).
Article CAS PubMed Google Scholar
Tyanova, S. et al. The Perseus computational platform for comprehensive analysis of (prote)omics data. Nat. Methods 13, 731–740 (2016).
Article CAS PubMed Google Scholar
Harris, M. A. et al. The Gene Ontology (GO) database and informatics resource. Nucleic Acids Res. 32, D258–D261 (2004).
Article CAS PubMed Google Scholar
Burrell, R. A., McGranahan, N., Bartek, J. & Swanton, C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature 501, 338–345 (2013).
Article CAS PubMed Google Scholar
Olive, P. L. & Banath, J. P. The comet assay: a method to measure DNA damage in individual cells. Nat. Protoc. 1, 23–29 (2006).
Article CAS PubMed Google Scholar
Nishimura, T. et al. Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency and redifferentiation. Cell Stem Cell 12, 114–126 (2013).
Article CAS PubMed Google Scholar
Bardeesy, N. & DePinho, R. A. Pancreatic cancer biology and genetics. Nat. Rev. Cancer 2, 897–909 (2002).
Article CAS PubMed Google Scholar
Papamichos-Chronakis, M. & Peterson, C. L. Chromatin and the genome integrity network. Nat. Rev. Genet. 14, 62–75 (2013).
Article CAS PubMed PubMed Central Google Scholar
Hakimi, M. A. et al. A chromatin remodelling complex that loads cohesin onto human chromosomes. Nature 418, 994–998 (2002).
Article CAS PubMed Google Scholar
Havugimana, P. C. et al. A census of human soluble protein complexes. Cell 150, 1068–1081 (2012).
Article CAS PubMed PubMed Central Google Scholar
Sarshad, A. et al. Nuclear myosin 1c facilitates the chromatin modifications required to activate rRNA gene transcription and cell cycle progression. PLoS Genet. 9, e1003397 (2013).
Article CAS PubMed PubMed Central Google Scholar
Sheu, J. J. et al. The roles of human sucrose nonfermenting protein 2 homologue in the tumor-promoting functions of Rsf-1. Cancer Res. 68, 4050–4057 (2008).
Article CAS PubMed PubMed Central Google Scholar
Tsai, Y. C., Greco, T. M., Boonmee, A., Miteva, Y. & Cristea, I. M. Functional proteomics establishes the interaction of SIRT7 with chromatin remodeling complexes and expands its role in regulation of RNA polymerase I transcription. Mol. Cell Proteom. 11, 60–76 (2012).
Article CAS Google Scholar
Wan, C. et al. Panorama of ancient metazoan macromolecular complexes. Nature 525, 339–344 (2015).
Article CAS PubMed PubMed Central Google Scholar
Zhao, X. C. et al. Overexpression of hSNF2H in glioma promotes cell proliferation, invasion, and chemoresistance through its interaction with Rsf-1. Tumour Biol. 37, 7203–7212 (2016).
Article CAS PubMed Google Scholar
Zhou, Y. et al. Reversible acetylation of the chromatin remodelling complex NoRC is required for non-coding RNA-dependent silencing. Nat. Cell Biol. 11, 1010–1016 (2009).
Article CAS PubMed Google Scholar
Hosoda, W. et al. Genetic analyses of isolated high-grade pancreatic intraepithelial neoplasia (HG-PanIN) reveal paucity of alterations in TP53 and SMAD4. J. Pathol. 242, 16–23 (2017).
Article CAS PubMed PubMed Central Google Scholar
Yachida, S. & Iacobuzio-Donahue, C. A. Evolution and dynamics of pancreatic cancer progression. Oncogene 32, 5253–5260 (2013).
Article CAS PubMed Google Scholar
Yachida, S. et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467, 1114–1117 (2010).
Article CAS PubMed PubMed Central Google Scholar
Uchi, R. et al. Integrated multiregional analysis proposing a new model of colorectal cancer evolution. PLoS Genet 12, e1005778 (2016).
Article PubMed PubMed Central CAS Google Scholar
Kinouchi, K. et al. The role of individual domains and the significance of shedding of ATP6AP2/(pro)renin receptor in vacuolar H(+)-ATPase biogenesis. PLoS One 8, e78603 (2013).
Article CAS PubMed PubMed Central Google Scholar
Berglund, L. et al. A genecentric Human Protein Atlas for expression profiles based on antibodies. Mol. Cell Proteom. 7, 2019–2027 (2008).
Article CAS Google Scholar
Bartkova, J. et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434, 864–870 (2005).
Article CAS PubMed Google Scholar
Ibarra, A., Schwob, E. & Mendez, J. Excess MCM proteins protect human cells from replicative stress by licensing backup origins of replication. Proc. Natl Acad. Sci. USA 105, 8956–8961 (2008).
Article CAS PubMed PubMed Central Google Scholar
Burrell, R. A. et al. Replication stress links structural and numerical cancer chromosomal instability. Nature 494, 492–496 (2013).
Article CAS PubMed PubMed Central Google Scholar
Wallace, S. S., Murphy, D. L. & Sweasy, J. B. Base excision repair and cancer. Cancer Lett. 327, 73–89 (2012).
Article CAS PubMed PubMed Central Google Scholar
Riha, K., Heacock, M. L. & Shippen, D. E. The role of the nonhomologous end-joining DNA double-strand break repair pathway in telomere biology. Annu. Rev. Genet. 40, 237–277 (2006).
Article CAS PubMed Google Scholar
Crnogorac-Jurcevic, T. et al. Proteomic analysis of chronic pancreatitis and pancreatic adenocarcinoma. Gastroenterology 129, 1454–1463 (2005).
Article CAS PubMed Google Scholar
Matsuda, Y. et al. Gradual telomere shortening and increasing chromosomal instability among PanIN grades and normal ductal epithelia with and without cancer in the pancreas. PLoS ONE 10, e0117575 (2015).
Article PubMed PubMed Central CAS Google Scholar
van Heek, N. T. et al. Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia. Am. J. Pathol. 161, 1541–1547 (2002).
Article PubMed PubMed Central Google Scholar
Clapier, C. R. & Cairns, B. R. The biology of chromatin remodeling complexes. Annu. Rev. Biochem. 78, 273–304 (2009).
Article CAS PubMed Google Scholar
Ray Chaudhuri, A. & Nussenzweig, A. The multifaceted roles of PARP1 in DNA repair and chromatin remodelling. Nat. Rev. Mol. Cell Biol. 18, 610–621 (2017).
Article CAS PubMed PubMed Central Google Scholar
Smeenk, G. et al. Poly(ADP-ribosyl)ation links the chromatin remodeler SMARCA5/SNF2H to RNF168-dependent DNA damage signaling. J. Cell Sci. 126, 889–903 (2013).
Article CAS PubMed Google Scholar
Zhivotovsky, B. & Kroemer, G. Apoptosis and genomic instability. Nat. Rev. Mol. Cell Biol. 5, 752–762 (2004).
Article CAS PubMed Google Scholar
Zhang, Y. et al. Canonical wnt signaling is required for pancreatic carcinogenesis. Cancer Res. 73, 4909–4922 (2013).
Article CAS PubMed PubMed Central Google Scholar
Harris, V. M. Protein detection by simple western analysis. Methods Mol. Biol. 1312, 465–468 (2015).
Article PubMed CAS Google Scholar
Dangles-Marie, V. et al. Establishment of human colon cancer cell lines from fresh tumors versus xenografts: comparison of success rate and cell line features. Cancer Res. 67, 398–407 (2007).
Article CAS PubMed Google Scholar
Kanda, M. et al. Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. Gastroenterology 142, 730–733 e739 (2012).
Article CAS PubMed Google Scholar
Gyori, B. M., Venkatachalam, G., Thiagarajan, P. S., Hsu, D. & Clement, M. V. OpenComet: an automated tool for comet assay image analysis. Redox Biol. 2, 457–465 (2014).
Article CAS PubMed PubMed Central Google Scholar
Neuber, K., Schmidt, S. & Mensch, A. Telomere length measurement and determination of immunosenescence-related markers (CD28, CD45RO, CD45RA, interferon-gamma and interleukin-4) in skin-homing T cells expressing the cutaneous lymphocyte antigen: indication of a non-ageing T-cell subset. Immunology 109, 24–31 (2003).
Article CAS PubMed PubMed Central Google Scholar
Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754–1760 (2009).
Article CAS PubMed PubMed Central Google Scholar
Li, H. et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078–2079 (2009).
Article PubMed PubMed Central CAS Google Scholar
Vizcaino, J. A. et al. ProteomeXchange provides globally coordinated proteomics data submission and dissemination. Nat. Biotechnol. 32, 223–226 (2014).
Article CAS PubMed PubMed Central Google Scholar
Okuda, S. et al. jPOSTrepo: an international standard data repository for proteomes. Nucleic Acids Res. 45, D1107–D1111 (2017).
Article CAS PubMed Google Scholar

Download references

Acknowledgements

We are grateful to Mr Kouichi Yube (Division of Research Instrument and Equipment, Kagawa University) for handling Flow Cytometry and ABI PRISM 3100 Genetic Analyzer, Mr Toru Matsunaga (Department of pathology, Kagawa University Hospital) for performing Papanicolaou stain, Ms Miho Seki (Department of Pharmacology, Faculty of Medicine, Kagawa University) for help with the western blotting and agarose gel electrophoresis, and Mr Yuji Yokota (Department of Pharmacology, Faculty of Medicine, Kagawa University) for taking care of the immunodeficient mice. Mr Koichi Ishiguro (AXIOHELIX Co. Ltd., Okinawa, Japan) also helped to perform the analysis of the human whole-genome sequence. Ms Kanako Ohtsuki created the images of Fig. 7. We also thank Edanz Group (www.edanzediting.com/ac) for editing a draft of this manuscript. This study was supported by Grants-in-Aid for Scientific Research (16K14610 and 19K07690 to Y.S. and 18H03191 to A.N.) from the Ministry of Education, Science and Culture of Japan and from the Tokyo Biomarker Innovation Research Associate (TOBIRA), the Hoansha Foundation and Alumni Association of Kagawa University (Sanjukai).

Author information

Authors and Affiliations

Department of Pharmacology, Faculty of Medicine, Kagawa University, Kagawa, 761-0793, Japan
Yuki Shibayama, Daisuke Yamazaki, Asadur Rahman & Akira Nishiyama
Department of Nephrology, Fujita Health University School of Medicine, Aichi, 470-1192, Japan
Kazuo Takahashi & Yukio Yuzawa
Division of Biomedical Polymer Science, Institute for Comprehensive Medical Science, Fujita Health University School of Medicine, Aichi, 470-1192, Japan
Hisateru Yamaguchi
Department of Medical Technology, School of Nursing and Medical Care, Yokkaichi Nursing and Medical Care University, Mie, 512-8045, Japan
Hisateru Yamaguchi
Department of Integrative Genomics, Tohoku Medical Megabank Organization, Tohoku University, Miyagi, 980-8573, Japan
Jun Yasuda
Division of Molecular and Cellular Oncology, Miyagi Cancer Center Research Institute, Miyagi, 981-1293, Japan
Jun Yasuda
Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Kagawa, 761-0793, Japan
Takayuki Fujimori, Hideki Kobara & Tsutomu Masaki
Fujimori Clinic for Internal Medicine and Gastroenterology, Kagawa, 761-8075, Japan
Takayuki Fujimori
Health Science Research Center, Faculty of Medicine, Kagawa University, Kagawa, 761-0793, Japan
Yoshihide Fujisawa
Department of Innovative Medicine, Graduate School of Medicine, Osaka Medical College, Osaka, 569-8686, Japan
Shinji Takai
Department of Investigative Pathology, Tohoku University Graduate School of Medicine, Miyagi, 980-8575, Japan
Toru Furukawa
Department of Applied Life Science, Faculty of Applied Biological Sciences, Gifu University, Gifu, 501-1193, Japan
Tsutomu Nakagawa
Department of Medical Biophysics, Kobe University Graduate School of Health Sciences, Hyogo, 654-0142, Japan
Hiroyuki Ohsaki
Department of Human Genetics, The University of Tokyo, Graduate School of Medicine, Tokyo, 113-0033, Japan
Jing Hao Wong & Akihiro Fujimoto
Community Medical Support, Tohoku Medical Megabank Organization, Tohoku University, Miyagi, 980-8573, Japan
Hideyasu Kiyomoto
Department of Cancer Genome Informatics, Faculty of Medicine, Graduate School of Medicine, Osaka University, Osaka, 565-0871, Japan
Shinichi Yachida

Authors

Yuki Shibayama
View author publications
You can also search for this author in PubMed Google Scholar
Kazuo Takahashi
View author publications
You can also search for this author in PubMed Google Scholar
Hisateru Yamaguchi
View author publications
You can also search for this author in PubMed Google Scholar
Jun Yasuda
View author publications
You can also search for this author in PubMed Google Scholar
Daisuke Yamazaki
View author publications
You can also search for this author in PubMed Google Scholar
Asadur Rahman
View author publications
You can also search for this author in PubMed Google Scholar
Takayuki Fujimori
View author publications
You can also search for this author in PubMed Google Scholar
Yoshihide Fujisawa
View author publications
You can also search for this author in PubMed Google Scholar
Shinji Takai
View author publications
You can also search for this author in PubMed Google Scholar
Toru Furukawa
View author publications
You can also search for this author in PubMed Google Scholar
Tsutomu Nakagawa
View author publications
You can also search for this author in PubMed Google Scholar
Hiroyuki Ohsaki
View author publications
You can also search for this author in PubMed Google Scholar
Hideki Kobara
View author publications
You can also search for this author in PubMed Google Scholar
Jing Hao Wong
View author publications
You can also search for this author in PubMed Google Scholar
Tsutomu Masaki
View author publications
You can also search for this author in PubMed Google Scholar
Yukio Yuzawa
View author publications
You can also search for this author in PubMed Google Scholar
Hideyasu Kiyomoto
View author publications
You can also search for this author in PubMed Google Scholar
Shinichi Yachida
View author publications
You can also search for this author in PubMed Google Scholar
Akihiro Fujimoto
View author publications
You can also search for this author in PubMed Google Scholar
Akira Nishiyama
View author publications
You can also search for this author in PubMed Google Scholar

Contributions

Y.S., H.Y., D.Y., A.R., Ta.F., Y.F., S.T. and H.O. performed the experiments. Y.S., J.Y., S.Y., A.F. and A.N. designed this study. Y.S., H.Y., J.Y., J.W., S.Y., A.F. and A.N. wrote the paper. Y.S., K.T., H.Y., J.Y., A.F., H.O. and A.N. performed the analyses and interpretation of data. K.T., J.Y., H.Ko., T.M., Y.Y., H.Ki., S.Y., To.F. and T.N. contributed to materials/analytical tools.

Corresponding authors

Correspondence to Akihiro Fujimoto or Akira Nishiyama.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Supplementary Information

Peer Review File

Description of Additional Supplementary Files

Supplementary Data 1

Supplementary Data 2

Supplementary Data 3

Supplementary Data 4

Supplementary Data 5

Reporting Summary

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Cite this article

Shibayama, Y., Takahashi, K., Yamaguchi, H. et al. Aberrant (pro)renin receptor expression induces genomic instability in pancreatic ductal adenocarcinoma through upregulation of SMARCA5/SNF2H. Commun Biol 3, 724 (2020). https://doi.org/10.1038/s42003-020-01434-x

Download citation

Received: 16 November 2018
Accepted: 23 October 2020
Published: 27 November 2020
DOI: https://doi.org/10.1038/s42003-020-01434-x

This article is cited by

Identification of multiple organ metastasis-associated hub mRNA/miRNA signatures in non-small cell lung cancer
- Lingling Zu
- Jinling He
- Song Xu
Cell Death & Disease (2023)
Mapping the protein binding site of the (pro)renin receptor using in silico 3D structural analysis
- Akio Ebihara
- Daiki Sugihara
- Fumiaki Suzuki
Hypertension Research (2023)

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.